A series of six experiments was conducted to investigate the effects of Mg deficiency in the young rat on parathyroid hormone (PTH) activity and on response to parathyroid extract (PTE) and to endogenously produced PTH stimulated by dietary Ca deficiency. Major criteria employed were 45Ca release from pre-labeled bone and urinary excretion of cAMP. Mg deficiency was accompanied by lowered 45Ca mobilization and urinary cAMP excretion, indicating either a depression in PTH secretion or tissue insensitivity to it. Administration of PTE resulted in equivalent increases in 45Ca mobilization irrespective of Mg status but increased cAMP excretion only in Mg-adequate animals, thus indicating a depressed sensitivity of kidney to PTH in the Mg-deficient animal. In vitro response of kidney cortex from Mg-deficient animals to PTE added to incubation medium indicated no defect in the adenyl cyclase system. Endogenous stimulation of PTH by low Ca diet increased cAMP in Mg-adequate animals but not in rats with pre-existing Mg deficiency. Mg deficiency did not reduce cAMP previously stimulated by Ca deficiency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jn/110.8.1610 | DOI Listing |
Background: Apart from massive weight loss, metabolic and bariatric surgery, especially gastric bypass (Roux-en-Y gastric bypass [RYGB]), can cause nutritional deficiencies. Proton pump inhibitors (PPI), relatively often used after RYGB, are associated with reduced calcium absorption. We have studied the long-term impact of PPI upon calcium homeostasis among RYGB patients.
View Article and Find Full Text PDFBMC Endocr Disord
January 2025
The Department of Thyroid Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Background: The importance of parathyroid gland preservation in thyroid surgery has been well recognized; however, the rapid identification of the parathyroid gland, particularly the inferior parathyroid gland (IPG), remains challenging. This study aimed to evaluate the effectiveness of retrograde inferior parathyroid protection technique (RIPPT) based on thymus preservation.
Methods: A total of 236 patients were enrolled in this study between August 2019 and December 2020.
Kidney Int
January 2025
Laboratório de Fisiopatologia Renal (LIM 16), Nephrology Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Universidade de São Paulo, São Paulo, Brazil. Electronic address:
In 2017, Kidney Disease: Improving Global Outcomes (KDIGO) published a Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Since then, new lines of evidence have been published related to evaluating disordered mineral metabolism and bone quality and turnover, identifying and inhibiting vascular calcification, targeting vitamin D levels, and regulating parathyroid hormone. For an in-depth consideration of the new insights, in October 2023, KDIGO held a Controversies Conference on CKD-MBD: Progress and Knowledge Gaps Toward Personalizing Care.
View Article and Find Full Text PDFJ Infect Dev Ctries
December 2024
Department of Gastroenterology, Pamukkale University School of Medicine, Denizli,Turkey.
Introduction: This study investigated the role of fibroblast growth factor 23 (FGF23)/Klotho in the mortality of patients hospitalized with coronavirus disease 2019 (COVID-19), excluding those with chronic kidney disease (CKD).
Methodology: A prospective cross-sectional study was conducted from April 2021 to May 2022. Patients who tested positive for COVID-19 via polymerase chain reaction and were hospitalized, were classified into two groups (survivors and non-survivors) at the end of their hospital follow-up.
Bone
January 2025
Research Institute, Meir Medical Center, Kfar Saba, Israel.
The objective of this retrospective, database study was to characterize the rate, magnitude and timeline of increases in parathyroid hormone (PTH) levels post-denosumab (DMAb) vs. zoledronic acid (ZA) injection in patients with osteoporosis and near normal baseline PTH. Included were osteoporotic females, ≥50 years, initiating treatment with 60 mg DMAb or 5 mg ZA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!